OptoVibronex, a life science startup, has developed non-invasive technology to help clinicians identify and characterize tissue types beneath the skin. Their proprietary Vibrational Optical Coherence Tomography (VOCT) technology measures tissue properties, such as stiffness, which can indicate cancer and predict metastatic potential.
Their Vibrational OptoScope device offers a “virtual biopsy,” providing a quick and quantifiable way for physicians to determine if a skin lesion is benign, pre-cancerous, or cancerous. Ben Franklin Northeast’s investment supported clinical trials at Summit Health in New Jersey and St. Luke’s University Health Network in Bethlehem, PA.
Other potential applications include ophthalmology, aesthetics, wound healing, orthopedics, and oncology.
